TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Brief Summary: The purpose of this study is to determine the safety and efficacy of intravenous magnesium in shortening the duration of a pain crisis and to determine the health-related quality of life and short term outcomes of children treated with intravenous magnesium during an acute pain crisis.


Options:
A: Arm Label: Stage 1; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 2; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 3; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 4; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Arm Label: Stage 2B; Type: EXPERIMENTAL; Interventions: Drug: Lexiscan | Intervention Type: DRUG; Name: Lexiscan; Assigned to Arm(s): Stage 1, Stage 2, Stage 2B, Stage 3, Stage 4
B: Arm Label: Magnesium group; Type: EXPERIMENTAL; Interventions: Drug: Intravenous Magnesium Sulfate | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline Placebo | Intervention Type: DRUG; Name: Intravenous Magnesium Sulfate; Assigned to Arm(s): Magnesium group | Intervention Type: DRUG; Name: Normal Saline Placebo; Assigned to Arm(s): Placebo group
C: Arm Label: Placebo Pills and Placebo Liquid; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Pills and Placebo Liquid | Arm Label: Hydroxyurea Pills and Placebo Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium Pidolate | Arm Label: Hydroxyurea Pills and Magnesium Pidolate Liquid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Drug: Magnesium Pidolate | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Hydroxyurea Pills and Placebo Liquid | Intervention Type: DRUG; Name: Magnesium Pidolate; Assigned to Arm(s): Hydroxyurea Pills and Magnesium Pidolate Liquid, Placebo Pills and Magnesium Pidolate Liquid | Intervention Type: OTHER; Name: Placebo Pills and Placebo Liquid; Assigned to Arm(s): Placebo Pills and Placebo Liquid
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulfate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Magnesium Sulfate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Do Phosphodiesterase 5A Inhibitors Improve Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension?
Brief Summary: The investigators hypothesise that phosphodiesterase 5A inhibitors will improve exercise capacity in those with Chronic Obstructive Pulmonary Disease and secondary pulmonary hypertension.


Options:
A: Intervention Type: DRUG; Name: Bosentan and Sildenafil; Assigned to Arm(s): N/A
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bosentan, Other: Placebo | Arm Label: Active; Type: EXPERIMENTAL; Interventions: Drug: Bosentan, Drug: Sildenafil Citrate | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Bosentan; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Sildenafil Citrate; Assigned to Arm(s): Active
C: Arm Label: Inhaled treprostinil; Type: EXPERIMENTAL; Interventions: Drug: Inhaled treprostinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo inhalation solution | Intervention Type: DRUG; Name: Inhaled treprostinil; Assigned to Arm(s): Inhaled treprostinil | Intervention Type: DRUG; Name: Placebo inhalation solution; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Tadalafil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tadalafil | Intervention Type: DRUG; Name: Tadalafil; Assigned to Arm(s): Tadalafil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-blind, Randomized, Right-left Study Comparing TEPSO® Socks With Standard Socks in Improving Palmoplantar Pustulosis
Brief Summary: The purpose of this study is to evaluate the efficacy of a special sock, manufactured using TEPSO®, compared to a normal cotton sock in the prognosis of symmetrical palmoplantar pustulosis present for at least one year.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CNTO 1959; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1959 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: CNTO 1959; Assigned to Arm(s): CNTO 1959
B: Arm Label: AIN457 150 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: secukinumab 150 mg, Drug: placebo to secukinumab 150 mg | Intervention Type: DRUG; Name: secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: placebo to secukinumab 150 mg; Assigned to Arm(s): AIN457 150 mg, AIN457 150mg from Placebo, AIN457 300 mg, AIN457 300mg from Placebo, placebo
C: Arm Label: AIN457 150mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: etanercept | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo, Etanercept, Placebo | Intervention Type: DRUG; Name: secukinumab (AIN457); Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept
D: Arm Label: TEPSO socks; Type: EXPERIMENTAL; Interventions: Device: TEPSO cloth | Arm Label: Standard socks; Type: PLACEBO_COMPARATOR; Interventions: Device: Standard cloth | Intervention Type: DEVICE; Name: TEPSO cloth; Assigned to Arm(s): TEPSO socks | Intervention Type: DEVICE; Name: Standard cloth; Assigned to Arm(s): Standard socks

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III, Randomized, Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy
Brief Summary: RATIONALE: Sulfasalazine may relieve diarrhea in patients with cancer who are undergoing pelvic radiation therapy.

PURPOSE: This randomized phase III trial is studying sulfasalazine to see how well it works in preventing acute diarrhea in patients with cancer who are undergoing pelvic radiation therapy.


Options:
A: Arm Label: Fiber supplement; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Inulin and Fructo-oligosaccharide | Arm Label: Maltodextrine; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrine | Intervention Type: DIETARY_SUPPLEMENT; Name: Inulin and Fructo-oligosaccharide; Assigned to Arm(s): Fiber supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrine; Assigned to Arm(s): Maltodextrine
B: Arm Label: Arm Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm Soy Supplement; Type: EXPERIMENTAL; Interventions: Drug: Soy Supplement | Intervention Type: DRUG; Name: Soy Supplement; Assigned to Arm(s): Arm Soy Supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm Placebo
C: Arm Label: Arm I: Sulfasalazine; Type: EXPERIMENTAL; Interventions: Drug: sulfasalazine | Arm Label: Arm II: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): Arm I: Sulfasalazine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II: Placebo
D: Arm Label: octreotide + radiation; Type: EXPERIMENTAL; Interventions: Drug: octreotide acetate, Radiation: radiation | Arm Label: placebo + radiation; Type: ACTIVE_COMPARATOR; Interventions: Other: placebo, Radiation: radiation | Intervention Type: DRUG; Name: octreotide acetate; Assigned to Arm(s): octreotide + radiation | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo + radiation | Intervention Type: RADIATION; Name: radiation; Assigned to Arm(s): octreotide + radiation, placebo + radiation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.
Brief Summary: The purpose of this study is to determine the effect of n-3 PUFAs in addition to amiodarone and renin-angiotensin-aldosterone system (RAAS) inhibitors on the maintenance of sinus rhythm after electrical conversion in patients with persistent Atrial fibrillation (AF).


Options:
A: Arm Label: n-3 PUFAs; Type: ACTIVE_COMPARATOR; Interventions: Drug: n-3 PUFAs, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Intervention Type: DRUG; Name: n-3 PUFAs; Assigned to Arm(s): n-3 PUFAs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: RASS inhibitors and/or RAS blockers; Assigned to Arm(s): n-3 PUFAs, placebo | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): n-3 PUFAs, placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega 3 (n-3 PUFA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3 (n-3 PUFA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: 1 Epanova; Type: EXPERIMENTAL; Interventions: Drug: Epanova | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Epanova | Intervention Type: DRUG; Name: Epanova; Assigned to Arm(s): 1 Epanova, 2 Placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.
Brief Summary: The purpose of this study is to determine the effect of n-3 PUFAs in addition to amiodarone and renin-angiotensin-aldosterone system (RAAS) inhibitors on the maintenance of sinus rhythm after electrical conversion in patients with persistent Atrial fibrillation (AF).


Options:
A: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: n-3 PUFAs; Type: ACTIVE_COMPARATOR; Interventions: Drug: n-3 PUFAs, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Intervention Type: DRUG; Name: n-3 PUFAs; Assigned to Arm(s): n-3 PUFAs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: RASS inhibitors and/or RAS blockers; Assigned to Arm(s): n-3 PUFAs, placebo | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): n-3 PUFAs, placebo
C: Arm Label: Safflower oil; Type: EXPERIMENTAL; Interventions: Other: Safflower oil | Arm Label: Control group (no diet instruction); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Safflower oil; Assigned to Arm(s): Safflower oil
D: Arm Label: Walnut group; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Walnuts | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: habitual diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Walnuts; Assigned to Arm(s): Walnut group | Intervention Type: OTHER; Name: habitual diet; Assigned to Arm(s): Control group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.
Brief Summary: The purpose of this study is to determine the effect of n-3 PUFAs in addition to amiodarone and renin-angiotensin-aldosterone system (RAAS) inhibitors on the maintenance of sinus rhythm after electrical conversion in patients with persistent Atrial fibrillation (AF).


Options:
A: Arm Label: Pikasol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pikasol | Arm Label: Corn oil; Type: PLACEBO_COMPARATOR; Interventions: Other: Corn oil | Intervention Type: DRUG; Name: Pikasol; Assigned to Arm(s): Pikasol | Intervention Type: OTHER; Name: Corn oil; Assigned to Arm(s): Corn oil
B: Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA
C: Arm Label: n-3 PUFAs; Type: ACTIVE_COMPARATOR; Interventions: Drug: n-3 PUFAs, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Intervention Type: DRUG; Name: n-3 PUFAs; Assigned to Arm(s): n-3 PUFAs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: RASS inhibitors and/or RAS blockers; Assigned to Arm(s): n-3 PUFAs, placebo | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): n-3 PUFAs, placebo
D: Arm Label: EPA + DHA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: EPA + DHA plus ALA; Type: EXPERIMENTAL; Interventions: Dietary Supplement: margarine spread | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: margarine spread | Intervention Type: DIETARY_SUPPLEMENT; Name: margarine spread; Assigned to Arm(s): ALA, EPA + DHA, EPA + DHA plus ALA, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in the Prevention of Atrial Fibrillation Recurrences After Electrical Cardioversion. A Prospective Randomized Study.
Brief Summary: The purpose of this study is to determine the effect of n-3 PUFAs in addition to amiodarone and renin-angiotensin-aldosterone system (RAAS) inhibitors on the maintenance of sinus rhythm after electrical conversion in patients with persistent Atrial fibrillation (AF).


Options:
A: Arm Label: n-3 PUFAs; Type: ACTIVE_COMPARATOR; Interventions: Drug: n-3 PUFAs, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: RASS inhibitors and/or RAS blockers, Drug: Amiodarone | Intervention Type: DRUG; Name: n-3 PUFAs; Assigned to Arm(s): n-3 PUFAs | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: RASS inhibitors and/or RAS blockers; Assigned to Arm(s): n-3 PUFAs, placebo | Intervention Type: DRUG; Name: Amiodarone; Assigned to Arm(s): n-3 PUFAs, placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zodin (drug) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olive oil (placebo) | Intervention Type: DRUG; Name: Zodin (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Olive oil (placebo); Assigned to Arm(s): 2
C: Arm Label: AMR101; Type: EXPERIMENTAL; Interventions: Drug: AMR101, Drug: Statin therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Statin therapy | Intervention Type: DRUG; Name: AMR101; Assigned to Arm(s): AMR101 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Statin therapy; Assigned to Arm(s): AMR101, Placebo
D: Arm Label: Omega 3 fatty acid (fish oil); Type: ACTIVE_COMPARATOR; Interventions: Drug: OMACOR | Arm Label: dummy pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: OMACOR; Assigned to Arm(s): Omega 3 fatty acid (fish oil) | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): dummy pill

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.


Options:
A: Arm Label: S-1 plus cisplatin; Type: EXPERIMENTAL; Interventions: Drug: s-1 plus cisplatin | Arm Label: 5-Fu plus cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fu plus cisplatin | Intervention Type: DRUG; Name: s-1 plus cisplatin; Assigned to Arm(s): S-1 plus cisplatin | Intervention Type: DRUG; Name: 5-Fu plus cisplatin; Assigned to Arm(s): 5-Fu plus cisplatin
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine, Drug: Oxaliplatin | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): 1
C: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla
D: Arm Label: Trastuzumab emtansine; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab emtansine | Arm Label: Lapatinib + Capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lapatinib, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab emtansine; Assigned to Arm(s): Trastuzumab emtansine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Lapatinib + Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Lapatinib + Capecitabine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.


Options:
A: Arm Label: Onartuzumab (MetMAb) with mFOLFOX6; Type: EXPERIMENTAL; Interventions: Drug: Onartuzumab (MetMAb), Drug: Oxaliplatin, Drug: Folinic acid, Drug: Levofolinic acid, Drug: 5-Fluorouracil | Arm Label: Placebo with mFOLFOX6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Oxaliplatin, Drug: Folinic acid, Drug: Levofolinic acid, Drug: 5-Fluorouracil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with mFOLFOX6 | Intervention Type: DRUG; Name: Onartuzumab (MetMAb); Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6, Placebo with mFOLFOX6 | Intervention Type: DRUG; Name: Folinic acid; Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6, Placebo with mFOLFOX6 | Intervention Type: DRUG; Name: Levofolinic acid; Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6, Placebo with mFOLFOX6 | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): Onartuzumab (MetMAb) with mFOLFOX6, Placebo with mFOLFOX6
B: Arm Label: S-1+Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm) | Arm Label: 5FU+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil/cisplatin (control arm) | Intervention Type: DRUG; Name: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm); Assigned to Arm(s): S-1+Cisplatin | Intervention Type: DRUG; Name: Fluorouracil/cisplatin (control arm); Assigned to Arm(s): 5FU+Cisplatin
C: Arm Label: S-1 plus cisplatin; Type: EXPERIMENTAL; Interventions: Drug: s-1 plus cisplatin | Arm Label: 5-Fu plus cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fu plus cisplatin | Intervention Type: DRUG; Name: s-1 plus cisplatin; Assigned to Arm(s): S-1 plus cisplatin | Intervention Type: DRUG; Name: 5-Fu plus cisplatin; Assigned to Arm(s): 5-Fu plus cisplatin
D: Arm Label: TE (Taxotere and Eloxatin); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin | Arm Label: TEF (Taxotere, Eloxatin and 5-FU); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + 5-FU | Arm Label: TEX (Taxotere, Eloxatin and Xeloda); Type: EXPERIMENTAL; Interventions: Drug: Docetaxel + Oxaliplatin + Capecitabine | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin; Assigned to Arm(s): TE (Taxotere and Eloxatin) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + 5-FU; Assigned to Arm(s): TEF (Taxotere, Eloxatin and 5-FU) | Intervention Type: DRUG; Name: Docetaxel + Oxaliplatin + Capecitabine; Assigned to Arm(s): TEX (Taxotere, Eloxatin and Xeloda)

Answer: C